JNJ - FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk
2024-04-19 06:13:03 ET
More on Bristol-Myers Squibb, Gilead, etc.
- Johnson & Johnson: Buy This Bargain Before It's Gone
- Bristol-Myers Squibb: Market Pessimism Won't Last Forever
- Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript
- FDA approves Alvotech biosimilar of J&J top-selling drug Stelara
- J&J sets guidance below consensus as MedTech underperforms